In patients with ulcerative colitis exposed to anti-TNF therapy, tofacitinib is linked to higher rates of clinical and steroid-free clinical remission than ustekinumab and vedolizumab.
Medscape News UK
Source link : https://www.medscape.com/viewarticle/which-drug-better-long-term-remission-patients-ulcerative-2026a1000lfs?src=rss
Author :
Publish date : 2026-06-26 12:00:00
Copyright for syndicated content belongs to the linked Source.
